Loading stock data…
Enliven Therapeutics (ELVN)
$59.37+0.05 (+0.08%)
Market ClosedLast close Sep 8
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enliven Therapeutics, Inc. in the Healthcare sector is trading at $59.37 with a market capitalization of $2.9B. Wall Street consensus targets $73.90 (10 analysts), implying a +24.5% move over the next 12 months. The stock is currently near its 52-week high of $62.32, remaining 57.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.21M↓ | -$27.82M↑ | -$34.28M↓ | -$25.10M↑ | -$28.58M |
| Net Income | -$32.48M↓ | -$23.63M↑ | -$29.67M↓ | -$20.15M↑ | -$25.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor whi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.79%
Volume
Today's trading volume
1.33M
Recent News
Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
Miners like Southern Copper and Newmont lead this screen of stocks to watch in or near buy range alongside UBS, Garmin and more.
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles
AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors.
HMI Capital Pares Its Stake in AI Company nCino
Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech.
Stocks To Watch: 14 Names Test And Tease New Buy Zones
A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags
Enliven Therapeutics has raced ahead with a 220.6% year to date return, yet the broader valuation checks and market multiples now lean toward the stock looking expensive rather than like an obvious bargain. The year to date gain of 220.6% suggests expectations around Enliven Therapeutics have reset significantly higher and leaves less room for disappointment. Upcoming work on the ENABLE-2 Phase 3 trial for ELVN-001 can support long term value if progress continues as planned, while recent...